Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer

Scott J. Hebbring, Henna Fredriksson, Kirsten A. White, Christiane Maier, Charles Ewing, Shannon K. McDonnell, Steven J. Jacobsen, James R Cerhan, Daniel J Schaid, Tarja Ikonen, Ville Autio, Teuvo L J Tammela, Kathleen Herkommer, Thomas Paiss, Walther Vogel, Marta Gielzak, Jurga Sauvageot, Johanna Schleutker, Kathleen A. Cooney, William IsaacsStephen N Thibodeau

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22% (2 of 909) for the probands and 0.25% (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples.

Original languageEnglish (US)
Pages (from-to)935-938
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Nijmegen Breakage Syndrome
Prostatic Neoplasms
Mutation
Genes
Familial Prostate cancer
Double-Stranded DNA Breaks
Mutation Rate

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. / Hebbring, Scott J.; Fredriksson, Henna; White, Kirsten A.; Maier, Christiane; Ewing, Charles; McDonnell, Shannon K.; Jacobsen, Steven J.; Cerhan, James R; Schaid, Daniel J; Ikonen, Tarja; Autio, Ville; Tammela, Teuvo L J; Herkommer, Kathleen; Paiss, Thomas; Vogel, Walther; Gielzak, Marta; Sauvageot, Jurga; Schleutker, Johanna; Cooney, Kathleen A.; Isaacs, William; Thibodeau, Stephen N.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 5, 05.2006, p. 935-938.

Research output: Contribution to journalArticle

Hebbring, SJ, Fredriksson, H, White, KA, Maier, C, Ewing, C, McDonnell, SK, Jacobsen, SJ, Cerhan, JR, Schaid, DJ, Ikonen, T, Autio, V, Tammela, TLJ, Herkommer, K, Paiss, T, Vogel, W, Gielzak, M, Sauvageot, J, Schleutker, J, Cooney, KA, Isaacs, W & Thibodeau, SN 2006, 'Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 935-938. https://doi.org/10.1158/1055-9965.EPI-05-0910
Hebbring, Scott J. ; Fredriksson, Henna ; White, Kirsten A. ; Maier, Christiane ; Ewing, Charles ; McDonnell, Shannon K. ; Jacobsen, Steven J. ; Cerhan, James R ; Schaid, Daniel J ; Ikonen, Tarja ; Autio, Ville ; Tammela, Teuvo L J ; Herkommer, Kathleen ; Paiss, Thomas ; Vogel, Walther ; Gielzak, Marta ; Sauvageot, Jurga ; Schleutker, Johanna ; Cooney, Kathleen A. ; Isaacs, William ; Thibodeau, Stephen N. / Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 5. pp. 935-938.
@article{56f671409a22422b87cf28db3cb32c1f,
title = "Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer",
abstract = "The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22{\%} (2 of 909) for the probands and 0.25{\%} (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples.",
author = "Hebbring, {Scott J.} and Henna Fredriksson and White, {Kirsten A.} and Christiane Maier and Charles Ewing and McDonnell, {Shannon K.} and Jacobsen, {Steven J.} and Cerhan, {James R} and Schaid, {Daniel J} and Tarja Ikonen and Ville Autio and Tammela, {Teuvo L J} and Kathleen Herkommer and Thomas Paiss and Walther Vogel and Marta Gielzak and Jurga Sauvageot and Johanna Schleutker and Cooney, {Kathleen A.} and William Isaacs and Thibodeau, {Stephen N}",
year = "2006",
month = "5",
doi = "10.1158/1055-9965.EPI-05-0910",
language = "English (US)",
volume = "15",
pages = "935--938",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer

AU - Hebbring, Scott J.

AU - Fredriksson, Henna

AU - White, Kirsten A.

AU - Maier, Christiane

AU - Ewing, Charles

AU - McDonnell, Shannon K.

AU - Jacobsen, Steven J.

AU - Cerhan, James R

AU - Schaid, Daniel J

AU - Ikonen, Tarja

AU - Autio, Ville

AU - Tammela, Teuvo L J

AU - Herkommer, Kathleen

AU - Paiss, Thomas

AU - Vogel, Walther

AU - Gielzak, Marta

AU - Sauvageot, Jurga

AU - Schleutker, Johanna

AU - Cooney, Kathleen A.

AU - Isaacs, William

AU - Thibodeau, Stephen N

PY - 2006/5

Y1 - 2006/5

N2 - The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22% (2 of 909) for the probands and 0.25% (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples.

AB - The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22% (2 of 909) for the probands and 0.25% (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples.

UR - http://www.scopus.com/inward/record.url?scp=33744718463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744718463&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0910

DO - 10.1158/1055-9965.EPI-05-0910

M3 - Article

C2 - 16702373

AN - SCOPUS:33744718463

VL - 15

SP - 935

EP - 938

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -